Skye Bioscience, Inc. Common Stock
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The compan… Read more
Skye Bioscience, Inc. Common Stock (SKYE) - Net Assets
Latest net assets as of September 2025: $32.84 Million USD
Based on the latest financial reports, Skye Bioscience, Inc. Common Stock (SKYE) has net assets worth $32.84 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($41.32 Million) and total liabilities ($8.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $32.84 Million |
| % of Total Assets | 79.46% |
| Annual Growth Rate | 86.47% |
| 5-Year Change | 15018.42% |
| 10-Year Change | 14369.7% |
| Growth Volatility | 571.46 |
Skye Bioscience, Inc. Common Stock - Net Assets Trend (2012–2024)
This chart illustrates how Skye Bioscience, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Skye Bioscience, Inc. Common Stock (2012–2024)
The table below shows the annual net assets of Skye Bioscience, Inc. Common Stock from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $68.15 Million | +3296.88% |
| 2023-12-31 | $-2.13 Million | +29.13% |
| 2022-12-31 | $-3.01 Million | -151.30% |
| 2021-12-31 | $5.86 Million | +1200.88% |
| 2020-12-31 | $450.79K | -17.75% |
| 2019-12-31 | $548.06K | +103.52% |
| 2018-12-31 | $-15.56 Million | -1845.09% |
| 2017-12-31 | $-800.08K | +44.86% |
| 2016-12-31 | $-1.45 Million | -408.05% |
| 2015-12-31 | $471.00K | +203.85% |
| 2014-12-31 | $-453.55K | -1143.99% |
| 2013-12-31 | $-36.46K | -194.55% |
| 2012-12-31 | $38.56K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Skye Bioscience, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28529440.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $30.98K | 0.05% |
| Other Components | $199.07 Million | 292.10% |
| Total Equity | $68.15 Million | 100.00% |
Skye Bioscience, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Skye Bioscience, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Plastiblends India Limited
NSE:PLASTIBLEN
|
$13.33 Million |
|
PRESSURE TECH.PLC LS -05
F:PRS
|
$13.34 Million |
|
Meshek Energy-Renewable Energies Ltd
TA:MSKE
|
$13.35 Million |
|
CKX Lands Inc
NYSE MKT:CKX
|
$13.36 Million |
|
NeoCore Technology Co., Ltd.
TWO:4131
|
$13.32 Million |
|
Philly Shipyard ASA
PINK:AKRRF
|
$13.32 Million |
|
Silver Viper Minerals Corp
OTCQB:VIPRF
|
$13.31 Million |
|
Silver Bullet Mines Corp.
OTCQB:SBMCF
|
$13.31 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Skye Bioscience, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -2,131,818 to 68,151,724, a change of 70,283,542.
- Net loss of 26,567,123 reduced equity.
- New share issuances of 83,556,563 increased equity.
- Other factors increased equity by 13,294,102.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-26.57 Million | -38.98% |
| Share Issuances | $83.56 Million | +122.6% |
| Other Changes | $13.29 Million | +19.51% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Skye Bioscience, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.36x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.59x to 0.36x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $1.13 | $0.67 | x |
| 2013-12-31 | $-5.33 | $0.67 | x |
| 2014-12-31 | $-10.80 | $0.67 | x |
| 2015-12-31 | $6.90 | $0.67 | x |
| 2016-12-31 | $-18.22 | $0.67 | x |
| 2017-12-31 | $-6.63 | $0.67 | x |
| 2018-12-31 | $-29.60 | $0.67 | x |
| 2019-12-31 | $1.03 | $0.67 | x |
| 2020-12-31 | $0.49 | $0.67 | x |
| 2021-12-31 | $3.61 | $0.67 | x |
| 2022-12-31 | $-0.01 | $0.67 | x |
| 2023-12-31 | $-0.30 | $0.67 | x |
| 2024-12-31 | $1.87 | $0.67 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Skye Bioscience, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -38.98%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.07x
- Recent ROE (-38.98%) is above the historical average (-189.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 11.69% | 27.76% | 0.38x | 1.11x | $653.10 |
| 2013 | 0.00% | -35.42% | 2.33x | 0.00x | $-102.19K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.69 Million |
| 2015 | -1027.86% | 0.00% | 0.00x | 7.45x | $-4.89 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.03 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.01 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.64 Million |
| 2019 | 191.95% | 0.00% | 0.00x | 3.64x | $997.19K |
| 2020 | -1455.46% | 0.00% | 0.00x | 5.93x | $-6.61 Million |
| 2021 | -145.33% | 0.00% | 0.00x | 1.68x | $-9.11 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-19.18 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-37.43 Million |
| 2024 | -38.98% | 0.00% | 0.00x | 1.07x | $-33.38 Million |
Industry Comparison
This section compares Skye Bioscience, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Skye Bioscience, Inc. Common Stock (SKYE) | $32.84 Million | 11.69% | 0.26x | $13.32 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |